THANK YOU FOR SUBSCRIBING
The company, which has raised over $124m in total funding, plans to use the funds to expand commercial operations worldwide and advance R&D into the detection of additional diseases as well as biomarkers indicating COVID-19 severity.
FREMONT, CA: Sight Diagnostics, a Tel Aviv, Israel-based maker of an FDA-cleared direct-from-fingerstick Complete Blood Count (CBC) analyzer, secured $71m in Series D funding. Investors included Longliv Ventures, Koch Disruptive Technologies, and OurCrowd.
The company, which has raised over $124m in total funding, plans to use the funds to expand commercial operations worldwide and advance R&D into the detection of additional diseases as well as biomarkers indicating COVID-19 severity.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Established in 2011 and led by Yossi Pollak, CEO and co-founder, Sight Diagnostics provides the Sight OLOⓇanalyzer, which automates the quantification and identification of different blood cell types and anomalies. Sight OLO delivers lab-grade CBC results by measuring 19 different blood parameters within minutes from either a fingerstick or a venous sample. In order to boost its AI-driven method, the company has generated a database of over half a petabyte of blood imagery, which is used to optimize Sight’s current diagnostic algorithms and explore new algorithms for the early detection of serious health conditions like sepsis and cancer, as well as blood factors impacting the severity of COVID-19.
Since receiving FDA 510(k) clearance for Sight OLO in late 2019, Sight has continued to expand its global reach with a specific focus on the US market. Thus far, the company has acquired contractual agreements with healthcare providers and distribution partners to deploy over 1,000 analyzers over the coming years and will use the funds raised to meet this demand. In parallel, Sight is also working with large pharmaceutical companies, including Pfizer, to support for different therapies and treatments.
More in News